CUSIP: 64052L106
Q1 2019 13F Holders as of 31 Mar 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
27,280,721
-
Share change
-
+2,170,069
-
Total reported value
-
$71,197,356
-
Put/Call ratio
-
108%
-
Price per share
-
$2.61
-
Number of holders
-
59
-
Value change
-
+$5,922,617
-
Number of buys
-
30
-
Number of sells
-
22
Quarterly Holders Quick Answers
What is CUSIP 64052L106?
CUSIP 64052L106 identifies NEOS - NEOS THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2019
-
Previous quarter:
Q4 2018
Recent filing periods for CUSIP 64052L106:
Institutional Holders of NEOS THERAPEUTICS INC - COM (NEOS) as of Q1 2019
As of 31 Mar 2019,
NEOS THERAPEUTICS INC - COM (NEOS) was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,280,721 shares.
The largest 10 holders included
Stonepine Capital Management, LLC, Nantahala Capital Management, LLC, BlackRock Inc., SPHERA FUNDS MANAGEMENT LTD., VANGUARD GROUP INC, FRANKLIN RESOURCES INC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Broadfin Capital, LLC, GOLDMAN SACHS GROUP INC, and STATE STREET CORP.
This page lists
59
institutional shareholders reporting positions in this security
for the Q1 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.